Bispecific Antibody Therapeutics Contract Manufacturing Market Size, Share and Trends Analysis, By Product Type (Monovalent Bivalent and Multivalent), By Route of Administration (Intravenous (IV), Subcutaneous (SC), and Others), By Stage of Development (Clinical Stage and Commercial Stage), By Fragment Type, By Indication, and By Region, Forecast 2025-2032

Bispecific Antibody Therapeutics Contract Manufacturing Market Overview and Key Insights:

The bispecific antibody therapeutics contract manufacturing market size reached USD 5,547.3 million in 2024 and is expected to register a revenue CAGR of 37.6% during the forecast period. Bispecific antibodies (bsAbs) are genetically engineered recombinant proteins with two distinct domains that bind to two antigens or epitopes at the same time. Bispecific antibody development is also driving advances in bioprocessing techniques, from expression to upstream processing and candidate purification.

Market Drivers:

Rising incidence of chronic diseases is a key driver of revenue growth in the bispecific antibody therapeutics contract manufacturing market. According to the American Cancer Society, in 2025, the United States is expected to see 36,110 new cases of multiple myeloma (20,030 males and 16,080 women). Approximately 12,030 deaths are projected (6,540 in males and 5,490 in women). In the United States, the average lifetime chance of developing multiple myeloma is less than 1%, or around 1 in 108 for men and 1 in 133 for women. However, each person’s risk may be higher or lower than this, depending on their risk factors.

These medications, most typically through T-cell activation, cause similar side effects such as cytokine release syndrome and immunological effector cell-associated neurotoxicity syndrome. Recent FDA approvals of BsAbs targeting CD3+ T cells related to CD20 for non-Hodgkin lymphoma and B-cell maturation antigen or GPRC5D for multiple myeloma have changed the therapy landscape for hematologic malignancies. Emerging new agents promise increased efficacy and safety by investigating novel antigen targets, novel structures such as trispecific antibodies, and the involvement of diverse immune cells.

On January 2025, Bora Biologics, a rapidly expanding division of Bora Pharmaceuticals, a leading contract development and manufacturing organization (CDMO), has announced that it will assist DotBio, a Singaporean biopharmaceutical company specializing in next-generation antibody therapies, in the development and manufacturing of DotBio’s lead asset, a novel tri-specific antibody codenamed DB007, against undisclosed cancer targets. Bora will help DotBio develop its lead asset, including its chemical, manufacturing, and controls (CMC) strategy, all the way through clinical development, from its 48,400-square-foot (4,500-square-meter) center of excellence in Zhubei, Taiwan.

Market Opportunity:

Emergence of next-gen BsAb formats acts as opportunities for bispecific antibody therapeutics contract manufacturing market. Bispecific antibodies (bsAbs) have received a lot of interest because of their dual binding activity, which allows for simultaneous antigen targeting and synergistic binding effects that go beyond what traditional monospecific antibodies can achieve. Advances in antibody engineering are constantly enhancing the stability and production efficiency of bsAbs.

Techniques like CrossMab and knobs-in-holes improve the manufacturability and usefulness of these complicated compounds. Nanobodies and TandAbs are two novel forms that are being explored to increase tissue penetration and specificity. These technological advances are critical for overcoming the inherent difficulties involved with the production and deployment of bsAbs.

Recent Trends:

Emerging trends include increasing outsourcing of manufacturing activities, advancements in bioprocessing technologies, and rise of modular and platform-based manufacturing approaches.

Bispecific antibodies (bsAbs) provide novel functions that have the potential to significantly improve therapeutic efficiency by targeting two different antigens at once. The immense therapeutic potential of bsAbs has resulted in the development of approximately 50 distinct recombinant bsAb forms. Platform manufacturing procedures are frequently highly attractive for businesses with pipelines containing several bispecific candidates. Such approaches enable rapid early-stage process development; provide time and cost efficiencies; reduce raw-material and consumables lead-times; and facilitate process transfers, analytical development, and regulatory filings.

Highly scalable Chinese hamster ovary (CHO) cell cultures can express proteins stably and at high titers, allowing them to compete with prokaryotic expression methods. Mammalian cell lines develop more slowly than prokaryotes, hence manufacturing takes longer.

Restraints & Challenges:

One of the most difficult aspects of developing bispecific antibodies is choosing the right target antigens. The targeted targets must be therapeutically appropriate and, ideally, complementary to enhance the therapeutic effect. Bispecific antibodies require more processing than monoclonal antibodies. The complicated nature of bsAbs makes it difficult to ensure good production, purity, and consistency. The right coupling of heavy and light chains is important to the antibody’s proper activity. Technologies such as the Duobody system and the “knobs-into-holes” technique have been developed to overcome these challenges, but precise optimization and control are still required in manufacturing.

Product Type Segment Insights and Analysis:

Based on the product type, the bispecific antibody therapeutics contract manufacturing market is segmented into monovalent bispecific antibodies and bivalent or multivalent bispecific antibodies.

Monovalent bispecific antibodies segment contributed the largest market share in 2024. Because of their broad range of functional capabilities, bispecific antibodies are becoming an increasingly important component of biologics in clinical development. Asymmetric monovalent bispecific IgGs (bsIgGs) have the added benefit of retaining their original antibody-like structure, which can result in good pharmacological and pharmacokinetic properties. There is still a need for quick preparation platforms to produce monovalent bsAbs, which often have mAb-like features such as a long in vivo half-life and the capacity to elicit Fc-effector functions. The first monovalent bsAbs were created utilizing knob-in-hole technology in the CH3 region of the Fc to enhance heterodimerization.

Fragment Type Segment Insights and Analysis:

Based on the fragment type, the bispecific antibody therapeutics contract manufacturing market is segmented into Bispecific T-Cell Engager (BiTE), Dual-Affinity Re-Targeting Proteins (DARTs), and Tandem diabodies (TandAbs).

Bispecific T-Cell Engager (BiTE) segment contributed the largest market share in 2024. Bispecific T cell engagers (BiTEs) are a new type of immunotherapeutic chemical that recruits T cells to tumor cells, facilitating the development of tumor immunotherapy. Recent research has focused on enhancing BiTE efficacy by treatment regimen optimization and molecular structure refinement. BiTEs have yielded many bispecific T cell-recruiting antibodies that have the potential to treat hematologic malignancies. The understanding of BiTE action mechanisms and newborn approaches for BsAb production can help improve the treatment of hematological malignancies.

Indication Segment Insights and Analysis:

Based on the indication, the bispecific antibody therapeutics contract manufacturing market is segmented into oncology, infectious diseases, neurological disorders, autoimmune and inflammatory disorders, and others.

Oncology segment contributed the largest market share in 2024. According to American Cancer Society, in the United States, approximately 13,360 new cases of invasive cervical cancer are expected to be detected in 2025.  Around 4,320 women will die from cervical cancer. Cervical pre-cancers are diagnosed far more frequently than invasive cervical cancer. Cervical cancer is most usually diagnosed in women aged 35 to 44, with an average age of 50.  It rarely develops in women under the age of twenty.

On April 2023, Lonza, a global development and production partner to the pharmaceutical, biotech, and nutrition industries, has signed a deal with ABL Bio, a pioneering Korean biologics business focused on bispecific antibodies for immuno-oncology and neurological illnesses. Lonza and ABL Bio have signed a collaboration agreement to support the development and manufacture of ABL Bio’s innovative bispecific antibody. As part of the agreement, Lonza provides ABL Bio with an end-to-end solution and integrated offering to help its bispecific antibody candidate progress from DNA to possible Investigational New Drug (IND) applications.

Geographical Outlook:

Bispecific antibody therapeutics contract manufacturing market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Bispecific Antibody Therapeutics Contract Manufacturing Market:

North America is registered to have the largest market share in bispecific antibody therapeutics contract manufacturing market in 2024. this is mainly driven by rising incidence of chronic diseases and technological advancements in antibody engineering. According to a report by the American Cancer Society, Acute Lymphocytic Leukemia (ALL) in the United States for 2025 (covering both children and adults), approximately 6,100 new cases of ALL (3,450 males and 2,650 females) and approximately 1,400 deaths from ALL (720 males and 680 females). Children under the age of five are most susceptible to developing ALL. The risk then gradually falls until the mid-20s, when it slowly begins to rise again beyond age 50. Overall, adults account for around four out of every ten instances of ALL.

On March 2025, ImmunoPrecise Antibodies Ltd. has established a strategic agreement with a leading biotechnology firm with a multibillion-dollar market capitalization to enhance the discovery and development of antibody-drug conjugates (ADCs) and bispecific antibodies for cancer treatment. This collaboration combines contract research skills with IPA’s patented B-cell Select platform and AI-driven discovery capabilities to improve the efficiency and precision of pharmaceutical development.

Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by increase in incidence of chronic diseases, growth of biopharmaceutical outsourcing, and increase in R&D of bispecific antibody. Bispecific antibodies (BsAbs) are now being researched and developed as cancer immunology therapy. This comprises a huge number of new entries, including biosimilar, bio generic, and bio better developer businesses, as well as new developers and CDMOs in developing nations including China, India, and South Korea. CDMO facilities and capacity must be dramatically expanded in emerging product technology areas such as cellular and gene treatments, antibody-drug conjugates (ADCs), and others.

India has seen an increase in the number of educational institutions dedicated to pharmaceutical and biopharmaceutical sciences and industry. With recent capacity additions, India can currently graduate over 500,000 engineers and 1.2 million scientists per year. For almost 30 years, Kemwell has been a 100% CDMO, servicing multinational pharmaceutical firms such as Bayer, Boehringer Ingelheim, GlaxoSmithKline, Merck KGaA, Novartis, and Pfizer, and selling goods to over 80 countries.

Europe Bispecific Antibody Therapeutics Contract Manufacturing Market:

Europe is expected to have considerable market share in 2024 driven by investments in single-use bioreactor technology. Furthermore, technological advancements in antibody engineering is also driving the market revenue growth in the region. On February 2025, Alloy Therapeutics Inc., a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, announced its most recent strategic collaboration with Pfizer Inc., to develop a new platform that could improve Pfizer’s ability to discover potent, specific, and effective antibodies against targets that are difficult to address with current antibody discovery technologies.

Competition Analysis:

The bispecific antibody therapeutics contract manufacturing market is characterized by a fragmented structure, with several players competing across various segments and regions. list of major players included in the bispecific antibody therapeutics contract manufacturing market report are:

• Creative Biolabs
• AbbVie
• Amgen
• Janssen
• WuXi Biologics
• Sino Biological Inc.
• evitria AG
• Lonza
• Roche
• Medelis
• Biointron Biologics
• MabPlex International Co. Ltd.
• Pure Biologics

Strategic Developments in Bispecific Antibody Therapeutics Contract Manufacturing Market:

• In December 2024, Porton Pharma Solutions and Dragon Sail Pharmaceutical Co., Ltd. have formally inked a strategic collaboration agreement in Guilin, southern China. This collaboration aims to conduct extensive research, development, manufacture, and supply chain integration for antibody-drug conjugates (ADC). This collaboration intends to provide a comprehensive one-stop service platform for ADC pharmaceuticals, covering the full process from bulk drug ingredients to finished products, early-stage discovery to commercial production.
• In October 2024, WuXi Biologics, a major worldwide Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the release of WuXia RidGS, a high-yield glutamine synthetase (GS) deletion Chinese hamster ovary (CHO) expression system platform. WuXia RidGS provides cell line stability for mAbs as well as other therapeutic modalities such as bispecific antibodies, Fc-fusion proteins, and recombinant proteins. The platform’s protein products demonstrate favorable glycosylation patterns while preserving an outstanding purity profile.
• In April 2024, Invenra Inc., an innovative leader in bispecific antibody technology, has announced a strategic partnership with Catalent, a global Contract Development and Manufacturing Organization (CDMO) that specializes in breakthrough drug development solutions. The collaboration will use Invenra and Catalent’s combined expertise and proprietary technology to discover innovative bispecific antibody-drug conjugates.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The Bispecific Antibody Therapeutics Contract Manufacturing Market Report:

The Bispecific Antibody Therapeutics Contract Manufacturing market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Product Type Outlook (Revenue, USD Million; 2022-2032)
  • Monovalent Bispecific Antibodies
  • Bivalent or Multivalent Bispecific Antibodies

• Route of Administration Outlook (Revenue, USD Million; 2022-2032)
  • Intravenous (IV)
  • Subcutaneous (SC)
  • Others

• Stage of Development Outlook (Revenue, USD Million; 2022-2032)
  • Clinical Stage
  • Commercial Stage

• Fragment Type Outlook (Revenue, USD Million; 2022-2032)
  • Bispecific T-Cell Engager (BiTE)
  • Dual-Affinity Re-Targeting Proteins (DARTs) 
  • Tandem diabodies (TandAbs)

• Indication Outlook (Revenue, USD Million; 2022-2032)
  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Autoimmune and Inflammatory Disorders
  • Others

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Bispecific Antibody Therapeutics Contract Manufacturing market report